The biotech has secured $65m in a Series A funding round led by Cormorant Asset Management and other investors.

The growth of AI in the healthcare sector is already having real-world impacts and promises a step-change in future care.

After missing primary endpoints in relapsing forms of MS, tolebrutinib has proved its efficacy in secondary progressive MS ...

Bavarian Nordic’s MVA-BN vaccine is called Imvanex in Europe but is known as Jynneos in countries such as the US and ...

Solving adherence issues with prodrugs, examining whether PBMs are to blame for high drugs prices in the US, developing ...

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended an update to Novo Nordisk’s ...

The NHS England has announced the routine commissioning of Daiichi Sankyo's quizartinib for acute myeloid leukaemia (AML).

The US FDA has declined to approve the NDA submitted by Vanda Pharmaceuticals for tradipitant to treat gastroparesis symptoms ...

RxCell has received a US patent for an iPSC-based cell therapy approach, a method of generating multiple cellular therapy ...

The Outsourcing in Clinical Trials New England conference will gather pharma experts to discuss the current clinical trial ...

Accord BioPharma received FDA approval for 420mg HERCESSI, a biosimilar to Herceptin to treat various kinds of ...

Before the FDA approved AstraZeneca’s Fasenra, Nucala was the only therapy for treating eosinophilic granulomatosis with ...